Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of Regen BioPharma Inc from 30 Sep 2021 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
- Summary
-
Regen BioPharma Inc quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 30 Sep 2021 to 31 Dec 2025.
- Regen BioPharma Inc Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 31 Dec 2025 was $64,977, a 11084% decline year-over-year.
- Regen BioPharma Inc annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2025 was $68,839.
- Regen BioPharma Inc annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $120,321, a 272% decline from 2023.
- Regen BioPharma Inc annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $69,833.
- Source SEC data
- View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)
Regen BioPharma Inc Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $64,977 | -$64,396 | -11084% | 01 Oct 2025 | 31 Dec 2025 | 10-Q | 13 Feb 2026 | 2026 | Q1 | |
| Q4 2024 | $581 | -$4,041 | -117% | 01 Oct 2024 | 31 Dec 2024 | 10-Q | 13 Feb 2026 | 2026 | Q1 | |
| Q4 2023 | $3,460 | 01 Oct 2023 | 31 Dec 2023 | 10-Q | 16 May 2025 | 2025 | Q1 |
Regen BioPharma Inc Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $68,839 | +$189,160 | 01 Oct 2024 | 30 Sep 2025 | 10-K | 30 Dec 2025 | 2025 | FY | |
| 2024 | $120,321 | -$190,154 | -272% | 01 Oct 2023 | 30 Sep 2024 | 10-K | 30 Dec 2025 | 2025 | FY |
| 2023 | $69,833 | +$745,790 | 01 Oct 2022 | 30 Sep 2023 | 10-K | 13 May 2025 | 2024 | FY | |
| 2022 | $675,957 | -$1,403,119 | -193% | 01 Oct 2021 | 30 Sep 2022 | 10-K | 15 Nov 2022 | 2022 | FY |
| 2021 | $727,162 | 01 Oct 2020 | 30 Sep 2021 | 10-K | 15 Nov 2022 | 2022 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.